SOPH (sophiagenetics.com) Company Total Asset Base

SOPH (SOPHiA GENETICS SA) - company brandmark

SOPHiA GENETICS SA (SOPH) is developing a cloud-based AI toolkit for genetic analysis and cancer combat, leveraging a unique patient dataset and extensive clinical integration. The business's success is based on the global growth of genetic testing and strict adherence to data privacy. The company's total assets amount to 188.01, which is clearly demonstrated by the price action on the GURU.Markets platform.

SOPHiA GENETICS S.A. (SOPH) - Cumulative Company Assets from 07/04/2022 to 10/29/2026

Financial and market metric breakdowns for sophiagenetics.com (SOPH)

- stock price and consensus target price:
Price Performance Chart SOPHiA GENETICS|SOPH - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization SOPH|SOPH - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Price of a Share SOPHiA GENETICS SA|SOPH - Company Net Assets|Market Value to Book Value sophiagenetics.com|SOPH - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio SOPHiA GENETICS SA|SOPH - Long-Term Debt to Capital|Current Liabilities to Capital SOPHiA GENETICS|SOPH - Company Aggregate Debts|Debt to Book Value Ratio SOPH|SOPH - Company Long-Term Debt|Short-Term Debt Volume SOPHiA GENETICS SA|Immediate Liquidity sophiagenetics.com
- earnings and valuation multiples indicators:
SOPH - Company Net Income
Fundamental valuation:SOPHiA GENETICS S.A.
Core merchandise of SOPHiA GENETICS SA

This indicator reflects the market value of all corporate resources, providing a real-time assessment of profit generation potential. By analyzing fluctuations in property and resources, an investor can track asset capitalization dynamics via a reverse return on assets (ROA) calculation. The metric is highly sensitive to exchange quotes, necessitating caution when interpreting sharp spikes. For SOPHiA GENETICS SA (SOPH), this confirms the effectiveness of cost optimization amid steady demand for genomic IT solutions.

Main competitors

veeva.com - Aggregate Asset Value|DOCS (Doximity) - Company Total Assets|HealthEquity Inc (HQY) - Company Total Asset Base|Cumulative Company Assets WAY (Waystar Inc.)|Aggregate Business Assets CRVL|Privia Health Group - Cumulative Company Assets|Aggregate Asset Value HURN|CERT - Aggregate Company Assets|Omnicell Inc (OMCL) - Cumulative Company Assets|GDRX: Company Total Assets|Company Assets Schrodinger Corp (SDGR)|PHR (Phreesia, Inc.) - Company Total Assets|Total Business Assets OMDA (omadahealth.com)|Aggregate Company Assets Evolent Health (EVH)|Company Total Asset Base HealthStream Inc|Aggregate Company Assets Definitive Healthcare Inc. DH|Consensus Corp (CCSI) - Company Assets|AGL - Aggregate Company Assets|Total Asset Value of Company ABSI|SY: Company Total Assets|National Research Corp. - Aggregate Asset Value|SPOK (Spok Corp) - Company Total Assets|OptimizeRx Inc. (OPRX) - Company Total Asset Base|Company Total Assets TBRG|Company Total Assets simulations-plus.com (SLP)|Health Catalyst - Cumulative Company Assets|Aggregate Asset Value CCLD|Research Solutions, Inc. - Company Total Assets|Company Balance Sheet Assets DLH Holdings Corp. (DLHC)|ONMD: Company Total Assets|Company Assets scienture.com (SCNX)|Aggregate Company Assets Healthcare Triangle, Inc.|Total Business Assets ISPC (iSpecimen Corp)|Company Total Assets BFRG|WORX - Company Assets|MSP Recovery Inc - Cumulative Company Assets|Aggregate Business Assets ICCT (iCoreConnect, Inc.)|TRxADE HEALTH - Company Total Assets|Company Total Asset Base Orgenesis Inc ORGS|RCM: Company Total Assets|Cumulative Company Assets Sharecare Inc|Aggregate Company Assets Streamline Health Solutions|syrahealth.com (SYRA) - Company Total Asset Base|Cumulative Company Assets AMEH (Apollo Medical Holdings)|MODN (Model N Inc) - Aggregate Asset Value|Aggregate Company Assets NextGen NXGN